Color Genomics
The MAGENTA and ProGen trials showed that
Germline Genetic Testing, Counseling Move Remote as Pandemic Limits In-Person Care Capacity
Many companies and counselors see the COVID-19 pandemic as a catalyst for moving germline risk testing into a digital-first healthcare model.
The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.
Hereditary Cancer Risk Variants Found in Significant Subset of Metastatic Breast Cancer Patients
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
Investigators used gene panel testing to assess hereditary breast and ovarian cancer risk in African American women with breast cancer, uncovering potential gaps in test access.
Mar 14, 2019